Clinical trials: CONTROL Condition
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug-Induced Liver Injury, Cholestatic Liver Injury
A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects
The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI)…
- Conditions
- Drug-Induced Liver Injury, Cholestatic Liver Injury, Mixed Liver Injury
- Trial name
- NCT06019936
- Testing
- MT2004 Capsule
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xi'An Aolitai Pharmaceutical Technology Co Ltd
Prader-Willi Syndrome
Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
This is a single-center, open-label, single-arm study with a double-blind, placebo-controlled, randomized withdrawal extension. Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are…
- Trial name
- NCT02034071
- Testing
- DCCR
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Essentialis, Inc.
Partial Edentulism, Tooth Disease
A Study of the Performance of Certain Prevail Implants Used in Short Fixed Cases
This prospective, randomized study evaluates the performance and crestal bone changes difference between the Osseotite Certain Prevail vs the non-lateralized design of the implant.
- Trial name
- RadioCity (NCT00723944)
- Testing
- Osseotite Certain Prevail, Osseotite Certain
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- ZimVie
Stress Urinary Incontinence
Safety and Efficacy Study of Regen Sling to Treatment SUI
To evaluate the treatment safety and efficacy of Regen Sling developed by medprin Regenerative Medical Technologies Co., Ltd. for female patients with stress urinary incontinence
- Trial name
- NCT02106299
- Testing
- Regen sling, tension-free vaginal tape-obturator(TVT-O)
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Medprin Regenerative Medical Technologies Co., Ltd.
Dermatitis, Allergic Contact
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.
- Trial name
- NCT00928447
- Testing
- rHuPH20
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Halozyme Therapeutics
Asthma
Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in terms of avoidance of corticosteroid use over…
- Trial name
- NCT03629249
- Testing
- QAW039 150 mg once daily, QAW039 450 mg once daily
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 604 people
- Sponsor
- Novartis Pharmaceuticals
Fibromyalgia
Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
To evaluate the efficacy of NYX-2925 versus placebo for the treatment of fibromyalgia.
- Trial name
- NCT04147858
- Testing
- NYX-2925
- Where
- 42 sites in United States
- Volunteers
- 310 people
- Sponsor
- Aptinyx
Juvenile Chronic Arthritis
Juvenile Rheumatoid Arthritis
The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.
- Trial name
- NCT00037648
- Testing
- Anakinra
- Volunteers
- 86 people
- Sponsor
- Amgen
Non Small Cell Lung Cancer
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new…
- Trial name
- NCT04379635
- Testing
- Tislelizumab, Cisplatin injection, Paclitaxel injection
- Where
- 44 sites in China
- Volunteers
- 453 people
- Sponsor
- BeiGene
Type 2 Diabetes Mellitus
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus.
- Trial name
- NCT00103935
- Testing
- Exenatide LAR
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Dry Eye Disease
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
- Trial name
- NCT07264517
- Testing
- GRF312 5%
- Where
- 10 sites in United States
- Volunteers
- 103 people
- Sponsor
- Instituto Grifols, S.A.
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major…
- Trial name
- CLARITY (NCT07484217)
- Testing
- Solriamfetol 150 MG
- Where
- 40 sites in United States
- Volunteers
- 508 people
- Sponsor
- Axsome Therapeutics, Inc.
Knee Osteoarthritis
Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee
The purpose of this study is to determine the safety and effectiveness of micronized dehydrated human amnion chorion membrane as compared to the 0.9% Sodium Chloride Injection, USP placebo control for the treatment of knee…
- Trial name
- NCT03485157
- Testing
- Micronized dHACM, Saline
- Where
- 17 sites in United States
- Volunteers
- 447 people
- Sponsor
- MiMedx Group, Inc.
Hereditary Angioedema, Angioneurotic Edema
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening.
- Conditions
- Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders
- Trial name
- NCT00262301
- Testing
- recombinant human C1 inhibitor
- Where
- 2 sites in Netherlands, Romania
- Volunteers
- 75 people
- Sponsor
- Pharming Technologies B.V.
Asthma
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire…
- Trial name
- FORTUNE (NCT03453112)
- Testing
- Foster 100/6µg NEXThaler, Foster 100/6µg pMDI
- Where
- 51 sites in China
- Volunteers
- 494 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Adult Attention Deficit Hyperactivity Disorder
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
- Trial name
- NCT03324581
- Testing
- OPC-64005, Atomoxetine
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Spinal Cord Injury, Orthostatic Hypotension
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
The goal of this interventional study is to evaluate the safety and preliminary effectiveness of the ARC-IM Therapy to improve hemodynamic management in people with sub-acute or chronic spinal cord injury.
- Trial name
- HemON-NL (NCT05941819)
- Testing
- ARC-IM Thoracic System implantation
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- ONWARD Medical, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).
- Trial name
- NCT01289119
- Testing
- Alogliptin, Metformin, Pioglitazone
- Where
- 21 sites in China, Hong Kong and 1 more
- Volunteers
- 506 people
- Sponsor
- Takeda
Cardiovascular Disease
The Fibrin Pad Cardiovascular Study
This is a three-arm, randomized multicenter study evaluating the safety and effectiveness of EVARREST™ Fibrin Sealant Patch in controlling mild to moderate vascular anastomosis suture line bleeding in cardiovascular surgery.
- Trial name
- NCT01681030
- Testing
- EVARREST™, Topical hemostat, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Ethicon, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.